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Abstract
BCOR has been recognized as a recurrently altered gene in a subset of pediatric tumors of the central nervous
system (CNS). Here, we describe a novel BCOR-CREBBP fusion event in a case of pediatric infiltrating astrocytoma
and further probe the frequency of related fusion events in CNS tumors. We analyzed biopsy samples taken from a
15-year-old male with an aggressive, unresectable and multifocal infiltrating astrocytoma. We performed RNA
sequencing (RNA-seq) and targeted DNA sequencing. In the index case, the fused BCOR-CREBBP transcript
comprises exons 1–4 of BCOR and exon 31 of CREBBP. The fused gene thus retains the Bcl6 interaction domain of
BCOR while eliminating the domain that has been shown to interact with the polycomb group protein PCGF1. The
fusion event was validated by FISH and reverse transcriptase PCR. An additional set of 177 pediatric and adult
primary CNS tumors were assessed via FISH for BCOR break apart events, all of which were negative. An additional
509 adult lower grade infiltrating gliomas from the publicly available TCGA dataset were screened for BCOR or
CREBBP fusions. In this set, one case was found to harbor a CREBBP-GOLGA6L2 fusion and one case a CREBBP-SRRM2
fusion. In a third patient, both BCOR-L3MBTL2 and EP300-BCOR fusions were seen. Of particular interest to this study,
EP300 is a paralog of CREBBP and the breakpoint seen involves a similar region of the gene to that of the index
case; however, the resultant transcript is predicted to be completely distinct. While this gene fusion may play an
oncogenic role through the loss of tumor suppressor functions of BCOR and CREBBP, further screening over larger
cohorts and functional validation is needed to determine the degree to which this or similar fusions are recurrent
and to elucidate their oncogenic potential.
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Introduction
Fusion transcripts are increasingly recognized as import-
ant oncogenic drivers in tumors of the central nervous
system (CNS). These include KIAA1549-BRAF, typically
resulting from tandem duplication and characteristic of
pilocytic astrocytoma [19], C11orf95-RELA in supraten-
torial ependymoma [32], and FGFR-TACC (e.g. FGFR3-
TACC3) in a subset of infiltrating gliomas [40], among
others. Recurrent fusion transcripts have additionally
been identified in pediatric infiltrating gliomas, including
those involving the MYB and MYBL1 loci [36]. As tu-
mors of the CNS continue to be profiled using RNA se-
quencing or other platforms to detect fusion transcripts,
it is likely that more fusion driver candidates will be
discovered.
BCL6 interacting co-repressor (BCOR), a gene whose
product has been shown to interact with histone deacety-
lases and enhances BCL6-mediated transcriptional repres-
sion [17], has recently been recognized as recurrently
altered in a subset of pediatric tumors of the CNS with
embryonal features. These tumors, termed “high grade
neuroepithelial tumor with BCOR alteration” (HGNET-
BCOR), are characterized in most cases by an internal tan-
dem duplication involving exon 15 of the gene [42]. Fu-
sion transcripts involving the BCOR gene have also been
described in a diversity of tumors extrinsic to the CNS in-
cluding clear cell sarcoma of the kidney [37, 48], ossifying
fibromyxoid tumors [21], acute promyelocytic leukemia
[50], endometrial stromal sarcoma (ESS) [27, 31], adult
non-uterine sarcoma [51], and a subset of small blue
round cell sarcomas [34, 35, 41].
More recently, EP300-BCOR alterations have been de-
scribed in pediatric gliomas [46]. Herein, we describe a
similar fusion event involving BCOR and CREBBP.
CREBBP is a paralogue of EP300 acetytransferase. The
identified fusion event has not been previously reported
in a pediatric infiltrating glioma, and we further explore
the extent to which these genes are altered in a broader
set of central nervous system tumors, including adult
gliomas.
Methods
Next-generation sequencing (NGS)
The Oncomine Comprehensive Assay v3 (OCAv3)
(ThermoFisher Scientific) was performed on the
IonTorrent™ S5 XL platform, following manufacturer
protocols (https://assets.thermofisher.com/TFS-Assets/
LSG/manuals/MAN0015885_OncomineComprehensiveAs
say_v3_UG.pdf
Last downloaded 12/27/2019). OCAv3 is an amplicon-
based targeted assay that enables the detection of rele-
vant SNVs, amplifications, gene fusions, and indels from
161 unique genes (Supplementary Table 1).
RNA sequencing and fusion confirmation by RT-PCR and
sanger sequencing
RNA sequencing (RNA-seq) and data processing was
performed as previously described [4, 7]. Briefly, RNA
was extracted from frozen material for RNA-seq using
the Promega Maxwell 16 MDx instrument (Maxwell 16
LEV simplyRNA Tissue Kit (cat. # AS1280)). Specimens
were prepared for RNA sequencing using the TruSeq
RNA Library Preparation Kit v2 or riboZero as previ-
ously described [4]. RNA integrity was verified using the
Agilent Bioanalyzer 2100 (Agilent Technologies). cDNA
was synthesized from total RNA using Superscript III
(Invitrogen). Sequencing was then performed on GAII,
HiSeq 2000, or HiSeq 2500 as paired-ends [4, 7]. All
reads were independently aligned with STAR_2.4.0f1
[11] for sequence alignment against the human genome
sequence build hg19, downloaded via the UCSC genome
browser http://hgdownload.soe.ucsc.edu/goldenPath/hg1
9/bigZips/, and SAMTOOLS v0.1.19 [25] for sorting and
indexing reads. Cufflinks (2.0.2) was used to estimate the
expression values (FPKMS), and GENCODE v19 GTF
file for annotation [9, 47]. For fusion analysis, we used
STAR-fusion (STAR-Fusion_v0.5.1), and FusionSeq
(v0.7.2) [15, 38] on publically available RNAseq data
available from the TCGA Research Network lower grade
glioma cohort. Fusions with significant support of junc-
tion reads and spanning pairs were then selected for
manual review.
For BCOR-CREBBP gene fusion analysis, PCR was per-
formed using custom PCR primers designed to amplify
short (approximately 200–400 bp) regions. A human
gDNA control sample was run in parallel to confirm
successful PCR and end-sequencing was performed
using PCR primers. After enzymatic purification, se-
quencing was achieved through BigDye Terminator
Cycle Sequencing. Data analysis was performed with
DNASTAR Lasergene12 software.
Fluorescence in-situ hybridization (FISH)
5 m-thick formalin-fixed paraffin-embedded (FFPE) tis-
sue sections were cut for FISH analysis, either as repre-
sentative whole slides of individual cases, or 3
representative 1 mm tissue cores per case integrated into
tissue microarrays. BCOR break apart was validated
using dual color FISH probes (RP11-973F20 BAC clone
labeled red; RP11-1082P20 labeled green). BCOR break
apart was determined as one individual green signal and
one individual red signal, per nucleus. CREBBP break
apart was validated using dual color FISH probes (RP11-
95P2 BAC clone labeled red; RP11-433P17 labeled
green). CREBBP break apart was determined as one indi-
vidual green signal, one individual red signal, and one
individual green and red signal overlapping, per nucleus.
BCOR-CREBBP fusion was determined using dual color
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FISH probes (BAC clone RP11-1082P20 labeled red;
RP11- RP11-433P17 labeled green). Fusion was mea-
sured as one individual green signal and one individual
green and red signal overlapping, per nucleus. Prior to
use, all clones were validated on metaphase spreads. A
minimum of 100 nuclei were observed per case using a
fluorescence microscope (Olympus BX51; Olympus Op-
tical, Tokyo, Japan). Cytovision and Fiji software were
used for imaging.
Immunohistochemistry
For BCOR staining, staining was performed at the Mayo
Clinic Laboratories in Rochester, MN on an FFPE 4 μm-
thick section from the index tumor case. A commercially
available antibody (Santa Cruz C10 monoclonal anti-
body) was used at a dilution of 1:250. Positive control
tissue comprised a FFPE tissue core of an Ewing-like sar-
coma with BCOR fusion.
Gene set enrichment analysis
We calculated z-scores comparing the index case with
82 infiltrating glioma samples over 67 patients (x- mean/
sd), from expression values. The z-scores were used as a
metric to rank the genes in the sample. The hypergeo-
metric test and Gene Set Enrichment Analysis (GSEA)
[43] was used to identify enriched signatures using the
different pathways collection in the online MSigDB
database (https://www.gsea-msigdb.org/gsea/msigdb/
index.jsp). We used the GSEA pre-ranked method which
takes the ranked gene list as an input. The infiltrating
glioma samples in the comparison group included 8
pediatric high grade gliomas (including two diffuse mid-
line gliomas), 8 IDH-mutated infiltrating astrocytomas, 9
oligodendrogliomas, and 42 IDH-wildtype infiltrating as-
trocytomas of which 35 had conventional histological
features of glioblastoma.
Results
A 15-year-old previously healthy boy presented with
new onset seizures. Magnetic resonance imaging (MRI)
demonstrated a non-contrast enhancing, expansile mass
involving the right frontal, left temporal and left occipital
lobes, consistent with an infiltrating glioma and demon-
strating a pattern of disease spread historically referred
to as “gliomatosis cerebri” (Fig. 1a, b). Right frontal cra-
niotomy and biopsy was performed followed by adjuvant
radiotherapy with concomitant temozolomide. Postoper-
ative MRI performed 18months later revealed progres-
sion of disease with a new area of enhancement
involving the right parietal lobe. The patient then under-
went partial tumor debulking and adjuvant radiotherapy
and chemotherapy (temozolomide, bevacizumab and
carboplatin). The patient continued to deteriorate
Fig. 1 Radiological and histological characteristics of the index case. Preoperative brain MRIs for the primary tumor demonstrated a mass
involving the right frontal lobe as well as the left occipital and temporal lobes (a, b). Representative histology of the primary tumor shows a
diffusely infiltrating astrocytoma with predominantly lower grade features (c). Re-resection material met histologic criteria for glioblastoma (d)
Pisapia et al. Acta Neuropathologica Communications            (2020) 8:80 Page 3 of 11
clinically and treatment was discontinued 27 months fol-
lowing initial biopsy.
Molecular characterization of genomic alterations
Histological evaluation of the initial biopsy tissue showed
a diffusely infiltrative astrocytoma with predominantly
low-grade features (Fig. 1c). A targeted next generation se-
quencing panel (Oncomine®v3) revealed truncating muta-
tions in NF1 and ARID1A. A TERT promoter mutation
was also present (Table 1). While the panel did not assess
for ATRX mutations, immunohistochemical analysis dem-
onstrated loss of expression of ATRX. In addition, tar-
geted PCR followed by Sanger sequencing and
immunohistochemistry was conducted to rule out muta-
tions of H3F3A at codons 27 and 34. If current recom-
mendations for the adult setting were to be applied, the
presence of TERT promoter mutation in combination
with an absence of IDH1/IDH2 mutation would be com-
patible with a diagnosis of diffuse astrocytic glioma, with
molecular features of glioblastoma, WHO grade IV [5].
Following chemoradiation, the patient underwent re-
resection of disease for recurrence and the histological fea-
tures, including markedly increased pleomorphism and
cellularity (Fig. 1d) as well as necrosis, were at this time
compatible with a histological diagnosis of glioblastoma
(Fig. 1d). Tissue from the re-resection material was not
available for molecular analysis.
Analysis of BCOR-CREBBP fusion transcript
Frozen tissue from the initial biopsy material was uti-
lized for RNA-seq followed by computational analysis
using FusionSeq. FusionSeq nominated a BCOR-
Table 1 Summary of molecular data interrogated by Oncomine,
PCR and immunohistochemistry
POSITIVE CALLS PERTINENT NEGATIVES
ARID1A p.Asp204fs mutations in IDH1, IDH2
TERT promoter mutation
c.-124C > T
H3 K27M and G34 by IHC and
PCR/Sanger
NF1 p.Trp696Ter EGFR amplification
ATRX loss of expression by IHC Remaining Oncomine Panel Targetsa
Next generation sequencing using the Oncomine® panel v3. Positive calls are
listed in the left column while selected pertinent negatives are listed in the
right column
aSee Supplementary Table 1 for a complete list of genes interrogated by the
Oncomine panel
Fig. 2 Description and validation of BCOR-CREBBP fusion product. Structure and functional domains of BCOR and CREBBP with the red line
indicating the fusion point (a). The detected fusion joins exon 4 of BCOR on chromosome X with exon 31 of CREBBP on chromosome 16 (b). RNA
sequencing demonstrated multiple reads in support of the fusion transcript (c). RT-PCR using primers for CREBBP and BCOR demonstrates a robust
PCR product (d). Sanger sequencing confirmed the chimeric DNA transcript, with the black dashed line indicating the fusion point (e)
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CREBBP fusion event with supporting evidence includ-
ing 18 junction reads and 33 spanning fragments (Fig. 2b
and c). The fusion product comprises exons 1–4 of
BCOR (with the break occurring at codon 901 in exon 4
at position chrX:39931896) and exon 31 of CREBBP
(with the break occurring at codon 1877 at position
chr16:3779417). The BCOR-CREBBP fusion was
predicted to be out-of-frame, creating a premature stop
codon within the CREBBP segment at codon 1965. The
reciprocal CREBBP-BCOR fusion transcript was not
detected by FusionSeq analysis.
Further validation was performed by reverse transcrip-
tion followed by PCR amplification of the putative fused
transcript, including the breakpoint (Fig. 2d). Sanger
sequencing of the amplified product further confirmed
the presence of the breakpoint detected by RNA-seq
(Fig. 2e). Disruption of the BCOR locus was additionally
demonstrated via FISH using a break-apart strategy and
probes recognizing loci 3′ and 5′ to the breakpoints of
BCOR on the X chromosome and CREBBP on chromo-
some 16 (Fig. 3a, b). A fusion FISH strategy was also
used to confirm colocalization of BCOR and CREBBP
(Fig. 3c).
Due to the unavailability of residual frozen tissue, we
were not able to perform Western blot analysis in an ef-
fort to detect a putative protein product. Immunohisto-
chemistry was performed on FFPE tissue sections with
an antibody developed against amino acids 1–300 of the
BCOR protein; however, we did not detect any labeling
in tumor cells in contrast to control tissue of an Ewing-
like sarcoma harboring a BCOR fusion (Supplementary
Fig. 1). While, this result could be due to failure of trans-
lation within tumor cells, we cannot exclude the possi-
bility that the antigenic epitope is masked in the putative
altered fused protein in our case, or that the staining
protocol was suboptimal for this tumor type.
Fusions involving BCOR or CREBBP are rare events in adult
and pediatric brain tumors
To explore whether the detected BCOR fusion is a re-
current event in primary brain tumors, break apart FISH
for the BCOR locus was performed on whole slides or
tissue microarrays comprising a diversity of central ner-
vous system neoplasms (Table 2). Out of 177 additional
screened cases, zero cases screened by FISH demon-
strated evidence of a BCOR fusion event.
To further screen a larger subset of infiltrating gli-
omas, analysis of RNA-seq data from The Cancer
Genome Atlas (TCGA) cohort of lower grade glioma pa-
tients (n = 509) was also conducted. The analysis yielded
four fusion transcripts relevant to the current study
(Fig. 4). Specifically, a 24-year-old female with an IDH-
wildtype high grade glioma harbored two fusions
involving BCOR, namely BCOR-L3MBTL2 as well as
EP300-BCOR, the latter with two distinct breakpoints
detected (Fig. 4b); a 30-year-old with anaplastic
Fig. 3 Fluorescent in situ hybridization (FISH) assays for BCOR and CREBBP in the index case. Break-apart green and red signals for BCOR (a) and
CREBBP (b) demonstrate gene rearrangement at the break points. For BCOR, only one allele is present, consistent with a single X chromosome in
this male patient. Fusion FISH assay shows the overlapping red and green signals in one allele (yellow signal), confirming BCOR-CREBBP fusion (c)
Table 2 Additional cases screened by break apart FISH for the
BCOR locus
Diagnosis Number of cases
Glioblastoma, adult 94
Oligodendroglioma, adult 19
Lower grade infiltrating astrocytoma, adult 17
Pilocytic astrocytoma 11
Ganglioglioma 6
Infiltrating glioma, pediatric 6
Medulloblastoma 6
Ependymoma 5
Meningioma 4
Pilomyxoid astrocytoma 4
Subependymal giant cell astrocytoma 2
Atypical teratoid/rhabdoid tumor 1
CNS Embryonal tumor, NOS 1
Pleomorphic xanthoastrocytoma 1
Total 177
Positive cases for BCOR break-apart signals 0
This table includes a list and number of tumor types screened via FISH for the
presence of a break apart event involving the BCOR locus, using
tissue microarrays
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astrocytoma, IDH-mutant, harbored a CREBBP-SRRM2
fusion (Fig. 4c); and a 45-year-old with anaplastic astro-
cytoma, IDH-wildtype, harbored a CREBBP-GOLGA6L2
fusion (Fig. 4d).
Furthermore, we compared the BCOR-CREBBP fusion
product in the present case to that of previously re-
ported chimeric transcripts involving BCOR rearrange-
ments with CREBBP or EP300 in ESS and pediatric
gliomas [25, 42]. The previously reported events include
BCOR-CREBBP and CREBBP-BCOR fusions in ESS, and
EP300-BCOR fusions in 3 cases of pediatric glioma. The
extent of the BCOR segment of the chimeric transcripts
was variable among the reported cases (Supplementary
Fig. 2). In the majority, exons 1–30 of CREBBP/EP300
were present in the resultant transcript with one case of
ESS showing the inverse, with only exon 31 included,
Fig. 4 Fusion proteins detected in TCGA cohort with genes relevant to this study. BCOR-CREBBP fusion product in the index case (a). TCGA-DU-
6404 is a 24-year-old female with IDH-wildtype high grade glioma harbored two fusions involving BCOR, namely BCOR-L3MBTL2 and BCOR-EP300
(b). TCGA-TM-A84I is a 30-year-old with IDH-mutant anaplastic astrocytoma harbored a CREBBP-SRRM2 fusion (c). TCGA-KT-A7W1 is 45-year-old
with IDH-wildtype anaplastic astrocytoma harbored a CREBBP-GOLGA6L2 fusion (d)
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similar to what is seen in the present case (Supplemen-
tary Fig. 2).
Gene set enrichment analysis of the index case
To probe potential downstream biological consequences
of BCOR and/or CREBBP alteration, we compared the
transcriptional profile of our index case to that of a co-
hort of 82 samples (over 67 patients) of adult and
pediatric infiltrating gliomas for which we had also per-
formed RNAseq. Unbiased gene set rich enrichment
analysis revealed two gene sets, among 50 predefined
HALLMARK gene sets [26], that demonstrated a nom-
inal p value for enrichment of < 0.05 and a false discov-
ery rate of < 0.05 [43]. These gene sets included those
relating to oxidative phosphorylation and targets regu-
lated by MYC (Supplemental Fig. 3). Interestingly there
is precedent in the cancer literature for MYC pathway
activation in the context of BCOR loss in T-cell lympho-
blastic leukemia and lymphomas [24, 44].
Discussion
Genetic alterations resulting in the generation of
chimeric fusion transcripts are increasingly recognized
as driving events in the oncogenic cascade. Gene fusions
have been described in a diversity of CNS tumors similar
to other tumor families, including hematopoietic neo-
plasms and sarcomas. For example, a tandem duplication
event linking BRAF to a nearby gene, KIAA1549, is a re-
current event seen in a majority of pilocytic astrocyto-
mas and represents the predominant neoplastic driver in
such cases. Certainly, fusion transcripts have also been
described not as singular events but in the setting of
multiple other well-described oncogenic events. For ex-
ample, those infiltrating gliomas with FGFR-TACC fu-
sions may present with other oncogenic alterations
including CDKN2A loss, CDK4 amplification, MDM2
amplification and/or TERT promoter mutations [10]. In
the present case, while well-characterized genes includ-
ing NF1 and ARID1A were detected using a targeted
DNA sequencing panel, analysis of RNA-seq data add-
itionally revealed a BCOR-CREBBP fusion event with
oncogenic potential that was validated by several other
modalities. FISH results suggest this gene fusion results
from chromosomal translocation.
Considering the domains represented in the resultant
putative BCOR-CREBBP fusion protein, it is possible
that this gene fusion has an oncogenic role. BCOR inter-
acts with polycomb group ring finger 1 (PCGF1) through
the PCGF Ub-like fold discriminator domain (PUFD) at
the C-terminus of BCOR, and is a constituent of the
polycomb repressive complex 1.1 (PRC1.1), which is in-
volved in the control of cell differentiation including by
the regulation of histone methylation marks [20]. Recent
in vivo studies suggest that the PUFD domain is
essential for a tumor suppressor function of BCOR and
that loss of BCOR promotes leukemogenesis [22, 45].
Moreover, next-generation sequencing studies have re-
vealed various BCOR alterations in a broad range of neo-
plastic diseases [2, 6, 29, 39]. In CNS tumors, loss of
function BCOR mutations (e.g., nonsense, frameshift,
splice sites and deletions) have been described in medul-
loblastoma, high-grade pediatric gliomas and astroblas-
tomas [2]. Given that the BCOR component of the
fusion transcript in the present case was truncated from
the middle of exon 4 and consequently lacks a PUFD
domain, the gene fusion product may be oncogenic in
part from a loss of tumor suppressor function of BCOR.
Moreover, since the BCOR gene is located on the X-
chromosome, the BCOR gene in the index case is
present as only one allele and the fusion event would
lead to a complete loss of putative tumor-suppressor ac-
tivity mediated by the PUFD. Another possibility is that
the residual BCOR segment fails to undergo translation
at all, as evidenced by the lack of immunohistochemical
staining in tumor cells. In this scenario, one possible
mechanism underlying this putative oncogenic activity
would be through upregulation of genes targeted by
MYC; indeed, our transcriptomic analysis reveals enrich-
ment of genes targeted by MYC, in a manner analogous
to what has previously been reported in T cell lympho-
blastic leukemia and lymphomas that have undergone
loss of BCOR [24, 44]. Transcriptomic analysis also re-
vealed upregulation of genes involved in oxidative phos-
phorylation, which may reveal fundamental shifts in
metabolic pathway utilization, exposing potential vulner-
abilities in tumors harboring this alteration.
Similar to BCOR, the fusion event involving CREBBP
(cAMP-response element binding protein-binding pro-
tein) potentially promotes gliomagenesis via disruption
of its tumor suppressor function. CREBBP acts as a
chromatin modifier with acetyltransferase activity and is
implicated in the transcriptional regulation of both de-
velopmental and neoplastic processes [13, 49]. In the
brain, this gene and its paralog, EP300, are altered in pa-
tients with Rubinstein-Taybi syndrome, a rare sporadic
neurodevelopmental disorder characterized by neuro-
cognitive deficits, autism-spectrum type behaviors and
gross anatomical abnormalities including facial dys-
morphism [16]. While the precise function of CREBBP
in tumor biology remains largely unknown, several stud-
ies have reported that CREBBP and its closely related
paralog EP300 behave as haploinsufficient tumor sup-
pressors [33, 53]. In cancer, CREBBP/EP300 is targeted
by both mutations and structural alterations. For ex-
ample, recent studies demonstrated that somatic inacti-
vating mutations of the histone-acetyltransferase (HAT)
domain of CREBBP/EP300 impair its acetyltransferase
activity in certain types of non-Hodgkin B-cell
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lymphoma and bladder cancer [12, 33]. In addition, pre-
vious data have detected loss of heterozygosity at the
EP300 or CREBBP loci in colorectal, gastric, ovarian,
and hepatocellular carcinomas [28]. Given that the
CREBBP component of the fusion transcript in our case
retains only exon 31 and consequently lacks most of the
functional domains, loss of CREBBP through this gene
fusion potentially promotes gliomagenesis. In contrast,
several studies suggest that CREBBP/EP300 can also me-
diate pro-oncogenic functions in some cell types [3].
Further experimental studies would be required in order
to clarify the biological role of CREBBP/EP300 in
gliomagenesis.
As discussed above, the fusion event in the present
case potentially exerts oncogenic activity via the loss of
both BCOR and CREBBP. While the pathogenic impact
of most reported gene fusions is gain-of-function, such
as constitutive kinase activation and abnormal activity of
transcriptional factors, fusions resulting in loss of func-
tion of tumor suppressors have been identified as well
[23, 30]. The APC-COMMD10 fusion in colorectal can-
cer is one example wherein fusion-mediated truncation
leads to a loss-of-function of tumor suppressors. In par-
ticular, Choi et al. suggested that the lack of functional
domains in APC resulting from the APC-COMMD10
gene fusion can lead to tumorigenesis [8] where loss of
APC is known to be a critical event in the development
of colon cancer [52]. Another example is RUNX1-
chromosome 9 fusion, which potentially contributes to
disease progression of myeloproliferative syndrome
through haploinsufficiency of RUNX1 [1].
Providing further support for the potential oncogen-
icity of this fusion is the recent discovery of similar fu-
sions in two completely unrelated tumor types. A fusion
involving CREBBP with BCORL1 has been described in
ossifying fibromyxoid tumors, with a similar breakpoint
region to that seen in our case, though with a distinct
predicted fusion transcript that preserves the HAT do-
main of CREBBP [21]. In addition, in a recently pub-
lished series of supratentorial ependymoma, a single case
demonstrated a fusion product between EP300 and
BCORL1, also with a similar breakpoint region exon 31
of EP300 and exon 4 of BCORL1, though here too the
authors predicted the fusion transcript would have pre-
served most functional domains in both proteins [14].
To examine the frequency of BCOR-CREBBP fusions
in CNS tumors more broadly, we analyzed RNA-seq
data from 509 cases of lower grade infiltrating gliomas
available through the TCGA and performed break apart
FISH for the BCOR locus for an additional 177 adult
and pediatric brain tumors. We did not find additional
cases with the same BCOR-CREBBP fusion from these
additional analyses, indicating that this fusion gene is
likely a rare event in CNS tumors. However, two
independent fusion events involving BCOR were found
in one TCGA case, BCOR-L3MBTL2 and EP300-BCOR.
In that case, the breakpoints seen in BCOR involve a
similar region of the gene to those in the present case,
and the BCOR-L3MBTL2 fusion transcript detected is
predicted to contain the first 4 exons of BCOR, as with
our case.
Given the rarity or this fusion in our study of add-
itional tumors, and the fact that additional oncogenic al-
terations were detected in this case, we cannot exclude
the possibility that the BCOR-CREBBP fusion represents
a stochastic passenger event without meaningful onco-
genic contribution. In particular, we recognize that one
recent study suggested that most gene fusions detected
by massively parallel sequencing are likely to be stochas-
tic passenger events [18]. We also acknowledge that the
majority of additional cases screened in this study are
from adult patients. Given that CNS tumors with previ-
ously reported BCOR alterations, such as BCOR ex15
ITD, EP300-BCOR fusions, and loss-of-function muta-
tions predominantly arise in pediatric or young adult pa-
tients, expanding analysis to larger cohorts enriched in
pediatric patients would be warranted and may increase
the chances of detecting further events involving
CREBBP and/or BCOR.
The clinicopathological features of our index case are
distinct from the previously reported pediatric gliomas
with EP300 and BCOR fusion events in several respects
[46]. First, radiological features in our case showed a
growth pattern consistent with “gliomatosis cerebri”,
while the previously reported gliomas with EP300-BCOR
fusions did not show this pattern to our knowledge. In
addition, whereas the previous study demonstrated that
cases with EP300-BCOR showed a myxoid to microcystic
background, frequent calcifications, and sometimes
piloid or even oligodendroglial-like features, these were
not observed in our case which at initial biopsy demon-
strated features of a classic infiltrating astrocytoma.
While tumors in the prior EP300-BCOR series demon-
strated rapid regrowth following resection, all patients
were alive at the time of that publication (6 mo – 3.5
yrs. of available follow-up). In our case the patient dem-
onstrated a relatively rapid disease course with high
grade progression and treatment discontinuation 27
months following initial biopsy.
Conclusion
We describe a rare BCOR-CREBBP fusion in a pediatric
patient with a high-grade infiltrating astrocytoma who
experienced progression and clinical deterioration within
27months. In an additional 686 primary CNS tumor
cases of adult and pediatric patients, assessed via FISH
or RNA-seq analysis, we identified an additional case
demonstrating a BCOR fusion to a paralog of CREBBP,
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namely EP300, similar to that seen in a recently reported
series. In addition, we detected three additional fusions
involving either BCOR or CREBBP, but with distinct
partners. These findings add to the existing literature
implicating BCOR as having a potential driving role in
CNS tumors. However, given that the BCOR-CREBBP
fusion here was not found to be recurrent and may rep-
resent a stochastic event, further screening and func-
tional studies are warranted to further define the
oncogenic potential of BCOR and related fusions in infil-
trating gliomas.
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